Kinexum congratulates TIXiMED on obtaining clearance from the US FDA to commence clinical testing of its TIX100.
WASHINGTON, DC, UNITED STATES, July 23, 2024 /EINPresswire.com/ -- Kinexum congratulates TIXiMED (www.tiximed.com) on obtaining clearance from the US FDA to commence clinical testing of its TIX100, an innovative small molecule targeting TXNIP, for Type 1 and Type 2 Diabetes. This is a major milestone in the development of the company’s novel approach to the treatment of Type 1 and Type 2 diabetes and gives TIXiMED the go ahead to start its human clinical trials with TIX100.Michael Zemel
Kinexum Services
michaelzemel@kinexum.com